Developer docs
API playgroundTry for free, no card

Search company profiles

HBT Labs

Full company profile

uuid000tkq5

Namestring
HBT Labs
Websiteurl
hbt-labs.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

HBT Labs is a privately held pharmaceutical company founded in 2013 and headquartered in Brea, California, with 11-50 employees. The company manufactures and supplies complex injectable medications — including epinephrine, iron sucrose (Venofer), sodium phosphates, potassium phosphates, zinc sulfate, and other FDA-approved formulations — for human and veterinary healthcare applications. Its core technology is pharmaceutical injectable manufacturing, a highly regulated discipline requiring FDA approval and complex formulation capabilities.

The company serves healthcare providers, hospitals, clinics, healthcare facilities, and veterinary practices, distributing products through an authorized pharmaceutical distributor network affiliated with American Regent, a Daiichi Sankyo Group Company. This affiliation provides access to global pharmaceutical expertise, distribution infrastructure, and a broader product portfolio than HBT Labs could independently support. The company also maintains an animal health product line via AR Animal Health.

HBT Labs operates a B2B pharmaceutical distribution model with non-publicly disclosed pricing, selling through authorized distributors with direct customer service support for healthcare facilities. No revenue, funding, or ownership details are publicly disclosed. The company is led by co-founder and president Don Hodgson and COO Janet Braun. The relationship between HBT Labs and American Regent — whether subsidiary, contract manufacturer, or affiliated entity — is not explicitly defined in available sources, though product and channel overlap is substantial.

Short descriptiontext

HBT Labs is a privately held pharmaceutical manufacturer (founded 2013, Brea, CA, 11-50 employees) that produces FDA-approved injectable medications including epinephrine, iron sucrose, and sodium phosphates for hospitals, clinics, and veterinary practices, distributing through an American Regent / Daiichi Sankyo affiliated network.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBrea, United States
HQ citystring
Brea
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
injectable pharmaceutical manufacturing, complex drug formulations, sterile injectables supply, FDA approved medicines, veterinary injectable drugs
Industry2 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAMAEAF
Pain Management, Anesthesia & Critical Care Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Injectable Pharmaceuticals
Social media profiles1 record
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Operations, Technology or R&D, Personnel, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

HBT Labs manufactures and supplies complex injectable pharmaceutical drugs—including epinephrine, iron sucrose, and sodium phosphates injections—based on advanced technology. The products are sold to hospitals, clinics, healthcare facilities, and veterinary practices for patient treatment.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Epinephrine Injection
CategoryInjectable Pharmaceuticals
Description

Injectable epinephrine formulation used for patient treatment in hospitals, clinics, and healthcare facilities.

2Iron Sucrose Injection
CategoryInjectable Pharmaceuticals
Description

Iron sucrose injectable formulation for patient treatment, supplied to healthcare providers.

3Sodium Phosphates Injection
CategoryInjectable Pharmaceuticals
Description

Sodium phosphates injectable formulation for patient treatment, distributed to hospitals, clinics, and veterinary practices.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global specialty/generic injectable and infusion therapy manufacturer competing across the same hospital injectable categories (iron, electrolytes, anesthesia) as HBT Labs, with broader portfolio and geographic reach.

TypeDirect peer
Description

Daiichi Sankyo Group Company that manufactures and distributes injectable pharmaceuticals including Venofer, Injectafer, and Gvoke. Operationally intertwined with HBT Labs and the most direct comparison given shared product set and customer base.

TypeBroad incumbent
Description

Major manufacturer of sterile injectable solutions, IV drugs, and infusion supplies serving hospitals and clinics in the U.S., with overlapping products such as sodium phosphates and IV fluids.

TypeDirect peer
Description

U.S. specialty injectable arm of Aurobindo Pharma marketing a wide range of sterile injectables in oncology, anti-infectives, and critical care, competing directly with HBT Labs' hospital channel offerings.

TypeEmerging player
Description

U.S. specialty injectable company focused on hospital essential medicines including sodium phosphates, electrolytes, and critical care injectables that overlap with HBT Labs' core portfolio.

TypeDirect peer
Description

U.S. injectables business (Hikma Injectables) markets a broad portfolio of generic sterile injectables including anti-infectives, oncology, and cardiovascular products sold into hospitals through similar distribution channels.

TypeDirect peer
Description

Specialty generic injectable company focused on hospital and surgical injectables, with overlapping molecules such as heparin, anti-infectives, and cardiovascular injectables.

TypeBroad incumbent
Description

Global hospital products manufacturer supplying injectable solutions, IV drugs, and anesthesia products into the same hospital channels as HBT Labs, including competing injectable electrolytes.

TypeDirect peer
Description

Specialty injectable pharmaceutical company with a portfolio including epinephrine, enoxaparin, and other hospital injectables, competing head-to-head with HBT Labs in several core SKUs.

TypeBroad incumbent
Description

Through Hospira, Pfizer is a leading global injectable pharmaceutical manufacturer with a portfolio that overlaps HBT Labs in hospital injectables, offering both broad scale and brand recognition.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HBT Labs

Injectable Pharmaceuticalshbt-labs.com

HBT Labs is a privately held pharmaceutical manufacturer (founded 2013, Brea, CA, 11-50 employees) that produces FDA-approved injectable medications including epinephrine, iron sucrose, and sodium phosphates for hospitals, clinics, and veterinary practices, distributing through an American Regent / Daiichi Sankyo affiliated network.

What HBT Labs does

HBT Labs is a privately held pharmaceutical company founded in 2013 and headquartered in Brea, California, with 11-50 employees. The company manufactures and supplies complex injectable medications — including epinephrine, iron sucrose (Venofer), sodium phosphates, potassium phosphates, zinc sulfate, and other FDA-approved formulations — for human and veterinary healthcare applications. Its core technology is pharmaceutical injectable manufacturing, a highly regulated discipline requiring FDA approval and complex formulation capabilities.

The company serves healthcare providers, hospitals, clinics, healthcare facilities, and veterinary practices, distributing products through an authorized pharmaceutical distributor network affiliated with American Regent, a Daiichi Sankyo Group Company. This affiliation provides access to global pharmaceutical expertise, distribution infrastructure, and a broader product portfolio than HBT Labs could independently support. The company also maintains an animal health product line via AR Animal Health.

HBT Labs operates a B2B pharmaceutical distribution model with non-publicly disclosed pricing, selling through authorized distributors with direct customer service support for healthcare facilities. No revenue, funding, or ownership details are publicly disclosed. The company is led by co-founder and president Don Hodgson and COO Janet Braun. The relationship between HBT Labs and American Regent — whether subsidiary, contract manufacturer, or affiliated entity — is not explicitly defined in available sources, though product and channel overlap is substantial.

HBT Labs firmographics

Firmographics
Name
HBT Labs
Website
https://hbt-labs.com
Company type
Private
Founded year
2013
Headcount range
11–50 employees
Short description
HBT Labs is a privately held pharmaceutical manufacturer (founded 2013, Brea, CA, 11-50 employees) that produces FDA-approved injectable medications including epinephrine, iron sucrose, and sodium phosphates for hospitals, clinics, and veterinary practices, distributing through an American Regent / Daiichi Sankyo affiliated network.
Ownership category
akta.pro rank

HBT Labs industry classification

Industry
Product category
Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAMAEAF
Pain Management, Anesthesia & Critical Care Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

  • Injectable pharmaceutical manufacturing
  • Complex drug formulations
  • Sterile injectables supply
  • FDA approved medicines
  • Veterinary injectable drugs

Where HBT Labs is headquartered

Location

Headquarters

HQ city
Brea
HQ country
United States
HQ region
North America

Markets served

HBT Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Supply Chain

Distribution channels1 record

HBT Labs product offering

Product offering

Core offering

HBT Labs manufactures and supplies complex injectable pharmaceutical drugs—including epinephrine, iron sucrose, and sodium phosphates injections—based on advanced technology. The products are sold to hospitals, clinics, healthcare facilities, and veterinary practices for patient treatment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Epinephrine Injection Injectable epinephrine formulation used for patient treatment in hospitals, clinics, and healthcare facilities.
  • Iron Sucrose Injection Iron sucrose injectable formulation for patient treatment, supplied to healthcare providers.
  • Sodium Phosphates Injection Sodium phosphates injectable formulation for patient treatment, distributed to hospitals, clinics, and veterinary practices.

Companies that use HBT Labs

Customer profile

Segments1 record

Ideal customer profiles1 record

HBT Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

HBT Labs partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights4 records

HBT Labs competitors and assessment

Company assessment

Broad incumbents

  • Fresenius Kabi: Global specialty/generic injectable and infusion therapy manufacturer competing across the same hospital injectable categories (iron, electrolytes, anesthesia) as HBT Labs, with broader portfolio and geographic reach.
  • B. Braun: Major manufacturer of sterile injectable solutions, IV drugs, and infusion supplies serving hospitals and clinics in the U.S., with overlapping products such as sodium phosphates and IV fluids.
  • Baxter International: Global hospital products manufacturer supplying injectable solutions, IV drugs, and anesthesia products into the same hospital channels as HBT Labs, including competing injectable electrolytes.
  • Pfizer (Hospira): Through Hospira, Pfizer is a leading global injectable pharmaceutical manufacturer with a portfolio that overlaps HBT Labs in hospital injectables, offering both broad scale and brand recognition.

Direct peers

  • American Regent: Daiichi Sankyo Group Company that manufactures and distributes injectable pharmaceuticals including Venofer, Injectafer, and Gvoke. Operationally intertwined with HBT Labs and the most direct comparison given shared product set and customer base.
  • Eugia US (Aurobindo): U.S. specialty injectable arm of Aurobindo Pharma marketing a wide range of sterile injectables in oncology, anti-infectives, and critical care, competing directly with HBT Labs' hospital channel offerings.
  • Hikma Pharmaceuticals: U.S. injectables business (Hikma Injectables) markets a broad portfolio of generic sterile injectables including anti-infectives, oncology, and cardiovascular products sold into hospitals through similar distribution channels.
  • Sagent Pharmaceuticals: Specialty generic injectable company focused on hospital and surgical injectables, with overlapping molecules such as heparin, anti-infectives, and cardiovascular injectables.
  • Amphastar Pharmaceuticals: Specialty injectable pharmaceutical company with a portfolio including epinephrine, enoxaparin, and other hospital injectables, competing head-to-head with HBT Labs in several core SKUs.

Emerging players

  • WG Critical Care: U.S. specialty injectable company focused on hospital essential medicines including sodium phosphates, electrolytes, and critical care injectables that overlap with HBT Labs' core portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

HBT Labs social profiles

Digital presence

HBT Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HBT Labs leadership team

Management profile

Number of profiles

Profiles2 records

HBT Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HBT Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HBT Labs

What does HBT Labs do?

HBT Labs manufactures and supplies complex injectable pharmaceutical drugs—including epinephrine, iron sucrose, and sodium phosphates injections—based on advanced technology. The products are sold to hospitals, clinics, healthcare facilities, and veterinary practices for patient treatment.

When was HBT Labs founded?

HBT Labs was founded in 2013. It employs 11 to 50 people.

Where is HBT Labs based?

HBT Labs is headquartered in Brea, United States, in the North America region.

Who are HBT Labs's main competitors?

Broad incumbents on record are Fresenius Kabi, B. Braun, Baxter International and Pfizer (Hospira). Direct peers are American Regent, Eugia US (Aurobindo), Hikma Pharmaceuticals, Sagent Pharmaceuticals and Amphastar Pharmaceuticals. WG Critical Care is listed as an emerging player.

Does HBT Labs have an API?

No public API is recorded for HBT Labs.

What industry is HBT Labs in?

HBT Labs's product category is Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAMAEAF, Pain Management, Anesthesia & Critical Care Drugs. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals